title: Cyclin D1, E2F1 expression levels are associated with characteristics and prognosis of esophageal squamous cell carcinoma.
abstract: SUMMARY. We performed a multi-institutional analysis of E2F1 and cyclin D1 expression in cases of esophageal squamous cell carcinoma (ESCC). Cyclin D1 and E2F1 are involved in the transition of cell cycle phases and associated with tumor progression. However, no previous studies have concurrently analyzed combined E2F1 and cyclin D1 expression. The purpose of this study was to clarify the relationship of E2F1 and cyclin D1 in ESCC. We studied 122 patients with primary ESCC who underwent surgical tumor resection. Immunohistochemical analyses were performed for E2F1 and cyclin D1. A statistical analysis of immunohistochemistry results, clinicopathological features, and prognosis was performed. E2F1/cyclin D1 (-/-) tumors were present in 31 patients (25.4%) and correlated with reduced tumor progression. In these patients, pT (P=0.0001), pN (P<0.0001), p-Stage (P=0.0019), and survival rates were better than in patients who were positive for either E2F1 or cyclin D1 (P=0.0232). The expression of E2F1 and cyclin D1 is an indicator of tumor progression and prognosis in patients with ESCC. Combined analysis of E2F1 and cyclin D1 expression helps to determine the characteristics and prognosis of ESCC.
authors.affiliation: Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. mega@med.hokudai.ac.jp
authors.forename: S
authors.initials: S
authors.lastname: Mega
authors.forename: M
authors.initials: M
authors.lastname: Miyamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Ebihara
authors.forename: R
authors.initials: R
authors.lastname: Takahashi
authors.forename: R
authors.initials: R
authors.lastname: Hase
authors.forename: L
authors.initials: L
authors.lastname: Li
authors.forename: T
authors.initials: T
authors.lastname: Shichinohe
authors.forename: Y
authors.initials: Y
authors.lastname: Kawarada
authors.forename: H
authors.initials: H
authors.lastname: Uehara
authors.forename: H
authors.initials: H
authors.lastname: Kaneko
authors.forename: H
authors.initials: H
authors.lastname: Hashimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Murakami
authors.forename: T
authors.initials: T
authors.lastname: Itoh
authors.forename: T
authors.initials: T
authors.lastname: Morikawa
authors.forename: S
authors.initials: S
authors.lastname: Kondo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000096:biosynthesis* / Q000235:genetics; D002294:Carcinoma, Squamous Cell / Q000235:genetics*; D018797:Cell Cycle Proteins / Q000096:biosynthesis* / Q000235:genetics; D019938:Cyclin D1 / Q000096:biosynthesis* / Q000235:genetics; D004268:DNA-Binding Proteins / Q000096:biosynthesis* / Q000235:genetics; D018450:Disease Progression; D050684:E2F Transcription Factors; D050687:E2F1 Transcription Factor; D004938:Esophageal Neoplasms / Q000235:genetics*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D014157:Transcription Factors / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D050684:E2F Transcription Factors; D050687:E2F1 Transcription Factor; C493753:E2F1 protein, human; D014157:Transcription Factors; D019938:Cyclin D1